BioSpace News Archive

Business

InspireMD Announces Third Quarter 2019 Financial Results

InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of carotid artery disease, announced financial and operating results for the third quarter ended September 30, 2019.

November 12, 2019
·
9 min read
Business

Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases

The companies will continue to collaborate to discover and develop the next generation of engineered alpha-beta T cells

November 12, 2019
·
5 min read
Business

Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights

Entered into Collaboration with bluebird bio to Evaluate Antibody-Based Conditioning Regimen in Combination with LentiGlobin

November 12, 2019
·
12 min read
Neovasc Reducer™ Therapy for Refractory Angina Exceeds 200th Patient Milestone in Germany

Neovasc, Inc. announced that a new milestone has been reached in Germany with the 200th patient implant of the Neovasc Reducer™

November 12, 2019
·
4 min read
Business

Covetrus Announces Financial Results for Third Quarter of 2019

Covetrus, a global leader in animal-health technology and services, announced financial results for the third quarter of 2019, which ended September 30, 2019.

November 12, 2019
·
12 min read
Business

Avadel Pharmaceuticals Reports Third Quarter 2019 Financial Results and Raises Revenue Guidance for FY2019

Enrollment currently at 200 patients for the pivotal REST-ON Phase 3 study (97.5% complete); the Company currently expects to complete patient enrollment by end of 2019, with data readout expected in Q2 2020

November 12, 2019
·
10 min read
Business

ContraFect Reports Third Quarter 2019 Financial Results and Provides Business Update

ContraFect Corporation announced financial results for the third quarter ended September 30, 2019.

November 12, 2019
·
10 min read
Business

Editas Medicine Announces Third Quarter 2019 Results and Update

Amended Celgene collaboration to focus on engineered alpha-beta T cell medicines with a $70 million payment to Editas Medicine

November 12, 2019
·
11 min read
Business

AGC Biologics’ $18m Investment in Seattle and Denmark Facilities Strengthens Global Footprint

AGC Biologics announced that their development and manufacturing capabilities at their Seattle, Washington and Copenhagen, Denmark facilities will be expanded, as part of an ongoing commitment to deliver the highest standard of service for their customers.

November 12, 2019
·
1 min read
Biomica Reports Positive Preliminary Results in Animal Studies in Its Immuno-oncology Program

Demonstrating Improved Anti-Tumor Activity Following Treatment with BMC 121 & BMC 127

November 12, 2019
·
6 min read